CAMBRIDGE, MA—Kathryn Jean Boor, a director at Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a $12.3 billion biotech company with a "GOOD" InvestingPro Financial Health score, has sold 1,636 shares of common stock, according to a recent SEC filing. The shares were sold at a price of $125.55 each, amounting to a total transaction value of $205,399. Following this transaction, Boor retains ownership of 5,880 shares in the company. The sale was conducted to generate cash for tax payments related to the vesting of restricted stock unit awards. The company's stock, which has delivered a 45% return over the past year, currently trades near $128, with five analysts recently revising earnings estimates upward. For deeper insights into insider trading patterns and comprehensive analysis, access the full InvestingPro Research Report, available for over 1,400 US stocks.
In other recent news, Sarepta Therapeutics has seen a flurry of activity with significant financial implications. The company's stock target was trimmed by H.C. Wainwright to $75, while maintaining a sell rating. This adjustment comes in the wake of Sarepta's licensing deal with Arrowhead Pharmaceuticals (NASDAQ:ARWR), which incorporates a variety of clinical and preclinical assets.
Sarepta's partnership with Arrowhead is expected to enhance its research and development capabilities, adding potentially 13 RNAi programs to its pipeline. The agreement includes a $500 million upfront payment, a $325 million equity investment in Arrowhead, and an additional $250 million over the next five years.
Analyst ratings from various firms, including BMO Capital, Piper Sandler, Needham, and Morgan Stanley (NYSE:MS), have maintained positive outlooks on Sarepta's stock. These firms have highlighted the strategic value of the Arrowhead deal and Sarepta's announced share repurchase program as evidence of its robust position.
Despite the positive ratings, some analysts have expressed caution, citing the need for compelling clinical evidence before incorporating the new programs into their valuation model. Sarepta's management has reaffirmed its expectation to remain cash flow positive, signaling a healthy financial state.
These recent developments are part of a broader pattern of strategic moves by Sarepta, which is expected to lead the company to profitability and positive cash flow. However, the effectiveness of RNAi therapeutics in tissues other than the liver remains to be proven, as no clinical data from the licensed programs is currently available.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.